BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.

NAME	POSITION TITLE
Waldemar Lernhardt	Chief Executive Officer
eRA Commons user name wlernhardt57	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Heidelberg, Heidelberg Germany University of Heidelberg, Heidelberg Germany Basel Institute for Immunology, Basel, Switzerland and University of Heidelberg, Heidelberg Germany	B.S. B.S. Ph.D.	1975 1976 1980	Chemistry Zoology/ Botany Immunology

A. Personal Statement

My personal goal, coinciding to develop and commercialize more definitive diagnostic and prognostic assays for prostate cancer and prostate cancer outcome. My experience in assay development, clinical trial design and management and general product development will be brought to bear on this project. Specifically, while working at Stratagene Cloning Systems I have developed and commercialized a number of molecular and cellular assays. During my tenure at Maxia Pharmaceuticals, Inc. I was engaged in all aspects of pharmaceutical R&D from drug discovery to Phase III clinical studies. I will assist with project management and workflow of the proposed project, data analysis, assay configuration and regulatory aspects.

B. Positions and Honors

1981-1983 1984-1988	Research Associate Assistant Staff Scientist	UCLA, School of Medicine, Los Angeles, CA La Jolla Cancer Res. Foundation, La Jolla, CA (now Sanford Burnham Institute for Medical	
		Research)	
1988 -1991	Research Program Director	California Inst. of Biological Res., La	
Jolla, CA			
1991 -1996	Staff Scientist, Cell Bio. Group Leade	er Stratagene Cloning Systems, Inc.,	
		La Jolla, CA	
1996	Director of Quality Control	Layton Bioscience, Inc., Palo Alto,	
CA,			
1997 - 2002	Vice President, Operations	Maxia Pharmaceuticals, Inc.	
2002 - 2003	Senior Vice President, Operations	Maxia Pharmaceuticals, Inc.	
2003	Vice President, Scientific Operations Incyte Corporation		
2005 - 2008	Vice President, Product Development	Therapeutics, Inc.	
2004 - Present	Chief Operations Officer	ARTYX Pharmaceuticals, Inc.	
2004 - Present	President & Chief Executive Officer	Proveri Inc.	
<u>Award</u>			

1981 – 1983 Postdoctoral fellowship, Deutsche Forschungsgemeinshaft.

Other Professional Experience

2010 Member, NCI Special Emphasis Panel: "SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization."

2011 Review Panel Member: Department of Defense Congressionally Directed Medical Research Programs; Prostate Cancer Research Program

2012 Initial Review Panel Member: Department of Defense Congressionally Directed Medical Research Lernhardt, Waldemar W

Programs; Prostate Cancer Research Program

C. Selected Peer-Reviewed Publications

- 1. Andersson, J., Coutinho, A., Lernhardt, W., Melchers, F. Clonal growth and maturation to immunoglobulin secretion of every growth-inducible B lymphocyte. **Cell** 10, 27-34 (1977). PMID: 319912.
- 2. Lernhardt, W., Andersson, J., Coutinho, A., Melchers, F. Cloning of murine transformed cell lines in suspension cultures with efficiencies near 100%. **Exp. Cell. Res**. 111, 309-316 (1978). PMID: 414926.
- 3. Boehmer, H.V., Hengartner, H., Nabholz, M., Lernhardt, W., Schreier, M.H., Haas, W. Fine specificity of a continuously growing killer cell clone specific for H-Y antigen. **Eur. J. Immunol**. 9, 592-297 (1979). PMID: 91527. PMCID: PMC2185729.
- 4. Andersson, J., Lernhardt, W., Melchers, F. The purified protein derivative of tuberculin, a B-cell mitogen that distinguishes in its action resting, small B cells from activated B cell blasts. **J. Exp. Med**. 150, 1339-1350 (1979). PMID: 315990.
- 5. Schreier, M.H., Andersson, J., Lernhardt, W., Melchers, F. Antigen-specific T-helper cells stimulate H-2-compatible and H-2-incompatible B-cell blasts polyclonally. **J. Exp. Med**. 151, 194-203 (1980). PMID: 6965306. PMCID: PMC2185768
- 6. Melchers, F., Andersson, J., Lernhardt, W., Schreier, M.H. H-2-unrestricted polyclonal maturation without replication of small B cells induced by antigen-activated T cell help factor. **Eur. J. Immunol**. 10, 679-685 (1980). PMID: 6968266
- 7. Melchers, F., Andersson, J., Lernhardt, W., Schreier, M.H. Roles of surface bound immunoglobulin molecules in regulating the replication and maturation to immunoglobulin secretion of B-lymphocytes. **Immunol. Rev.** 52, 89-114 (1980). PMID: 7021398.
- 8. Lernhardt, W., Corbel, C., Wall, R., Melchers, F. T cell hyridomas which produce B lymphocyte replication factors only. **Nature** 300, 355-357 (1982). PMID: 6983034
- 9. Melchers, F., Lernhardt, W. Three restriction points in the cell cycle of activated murine B-lymphocytes. **Proc. Natl. Acad. Sci. USA** 82, 7681-7685 (1985). PMID: 3877931. PMCID: PMC391397.
- 10. Lernhardt, W., Raschke, W.C., Melchers F. Alpha-type B cell growth factor and complement component C3: Their possible structural relationship. **Current Topics in Microbiol. and Immunol**. 132, 98-104 (1986). PMID: 3491740
- 15. Lernhardt, W., Karasuyama, H., Rolink, A., Melchers, F. Control of the cell cycle of murine Blymphocytes:
- The nature of a and b B cell growth factors and B cell maturation factors. **Immunol. Rev**. 99, 239-260 (1987). PMID: 3315969
- 12. Lernhardt, W., Melchers, F. The role of C3 and its fragments in the control of S phase entry of activated mouse B-lymphocytes via the complement receptor type 2. **Expl. Clin. Immunogenet**. 5, 115-122 (1988). PMID: 2978811
- 13. DeCino, P., Lernhardt, W., Herbst, H., Raschke, W.C. Expression of oncogenes in normal and transformed B lymphocytes. **Oncogene Res**. 3, 33-37 (1988). PMID: 3264606
- 14. Delcayre, A.X., Salas, F., Mathur, S., Kovats, K., Lotz, M., Lernhardt, W., Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. **EMBO J**. 10(4), 919-26 (1991). PMID: 1849076. PMCID: PMC452735.
- 15. Jia, Z., Wang, Y., Sawyers, A., Yao, H., Rahmatpanah, F., Xia, X-Q. Xu, Q., Pio, R., Turan, T., Koziol, J.A., Goodison, S., Carpenter, P., Wang-Rodriquez, J., Simoneau, A., Meyskens, F., Sutton, M., Lernhardt, W., Beach, T., Monforte, J., McClelland, J., and Mercola, D., Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma. **Cancer Research** 71:2476-2487 (2011).

16. Jia, Z, Rahmatpanah, F.B., Chen, X., Lernhardt, W., Wang, Y., Xia, X.-Q., Sawyers, A., Sutton, M., McClelland, M., Mercola, D., Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse. **PLoS One** 7 (2012).

17. Jia, Z., Wang, Y., Hu, Y., McLaren, C., Yu, Y., Ye, K., Xia, X.-Q., Koziol, J.A., Lernhardt, W., McClelland, M., Mercola, D., A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies. **Anti-Cancer Agents in Medicinal Chemistry**, 13:0000-0000 (2013). Lernhardt, Waldemar W

D. Research Support ACTIVE: None